Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses RNAi Patents to MWG Biotech

NEW YORK, July 25 (GenomeWeb News) - Alnylam Pharmaceuticals has licensed its RNA interference patents to MWG Biotech, the company said today.

 

Under the non-exclusive license to Alnylam's Kreutzer-Limmer patent family, MWG is allowed to provide research products and services in RNA interference.

 

The patent family covers short interfering RNAs and their use in mammalian cells. To date, 14 companies have licensed the patents, including eight research tool providers, according to Alnylam. Last week, Sigma-Aldrich became a licensee.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.